

Welcome and Opening Remarks

Center for Substance Abuse Prevention

Drug Testing Advisory Board

Ron Flegel, BSMT (ASCP), MS
DTAB Chair

Substance Abuse and Mental Health Services Administration
U.S. Department of Health and Human Services

December 4, 2018
Open Session—Public



SAMHSA
Substance Abuse and Mental Health
Services Administration

Division of Workplace Programs

- Director: Ron Flegel, B.S., MT(ASCP), M.S.
- Contracting Officer Representative: CDR Eugene D. Hayes, Ph.D., M.B.A.
- Senior Pharmacology and Regulatory Policy Advisor: CAPT Sean J. Belouin, Pharm.D.
- Toxicologist: Vacant
- Policy Analyst: Ana Donovan
- Senior Chemist: Charles LoDico, M.S., F-ABFT
- Senior Policy Analyst: Coleen Sanderson
- Policy Oversight Lead: Hyden Shen, J.D.
- Senior Research Analyst: Deborah Galvin, Ph.D.
- Program Assistant: Jeannette Talavera

Regulation Policy

Donor
Drug Test
Result

Medical Review Officers
Trained Collectors
HHS-Certified Laboratories
National Laboratory Certification Program
Federal Agency Plan and TDP List
Mandatory Guidelines

Drug Testing Advisory Board
Interagency Coordinating Group Executive Committee
Division of Workplace Programs
Office of National Drug Control Policy
Executive Order 12564 – Public Law 100-71


Drug Free Workplace Programs




Federal Laws



Testing Issues



State Laws



Contract / Legal Issues

DWP Objectives and Goals

- **Goals:** Establish an implementation date for the Mandatory Guidelines using Oral Fluid. Establish the proposed final Mandatory Guidelines using hair and refer to Office of Management and Budget for review.
- **Present:** Receive final approval for Mandatory Guidelines using oral fluid as an alternative specimen to enhance the Federal Workplace Drug Testing Program
- **Future:** Referral of the Proposed draft Hair Mandatory Guidelines to the Office of Management and Budget for distribution to all federal agencies for comments and review.

Revised Urine Mandatory Guidelines

- Federal Register was published January 23, 2017
 - 82 FR 7920, Pages 7920-7970
- Implementation date: October 1, 2017 (13 months ago)
- Reiterate the Changes
 - Added oxycodone, oxymorphone, hydrocodone, hydromorphone
 - Removed MDEA
 - Added MDA as initial testing analyte
 - Raised lower pH cutoff level for adulterated specs [3 → 4]
 - Many wording changes to address alternative specimens when authorized

Drug Testing Panel

1) Cocaine

2) Amphetamines

3) Marijuana

4) Phencyclidine (PCP)

5) Opioids

- Hydrocodone
- Hydromorphone
- Oxycodone
- Oxymorphone

6) Emerging Drugs

Note: If the Agency desires to add any other drug to its drug testing panel, advance written approval from the Secretary, Department of Health and Human Services is required. However, the Agency may test for any other Schedule I or Schedule II drug on a case by case basis.

Effective Date: October 1, 2017

- DWP continues to follow up with Federal Agency Drug Program Coordinators that oversee the agencies DFWP - consistent with the requirements in the MG and testing of opioids.
- HHS Secretary's priority has continued to be the Opioid crisis. The testing for the synthetic Opioids could help deter the illicit use of prescription opioids and provide treatment for employees in federal agencies.
- The New federal chain of custody form (CCF) is in effect for Federal Agencies and regulated testing. Use of the previous (2014) CCF was extended until June 1, 2018 but is no longer an approved CCF.

Patients and Communities Act, P.L. 115-271

- Fighting Opioid Abuse in the Transportation Act: enacted Oct. 24, 2018
- SEC. 8107. Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid.
- Deadline.-Not later than December 31, 2018, the Secretary of Health and Human Services shall publish in the Federal Register a final notice of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid, based on the notice of proposed mandatory guidelines published in the Federal Register on May 15, 2015 (94 FR 28054)
- Requirement.-To the extent practicable and consistent with the objective of the testing described in subsection (a) to detect illegal or unauthorized use of substances by the individual being tested the final notice of scientific and technical guidelines under that subsection, as determined by the Secretary of Health and Human Services, shall eliminate the risk of positive test results, of the individual being tested caused solely by the drug of others and not caused by the drug use of the individual being tested.

Oral Fluid Mandatory Guidelines

- Marijuana Studies
 - Technical and Scientific Peer Reviewed Journal Articles
 - DWP continues to update this list of reference articles
 - Thank you to Dr. Ed Cone and Dr. Ryan Vandrey as Principle Investigators
 - Studies (CBD) and data for marijuana analytes are under review.
- Federal Register Notice: 2018?
- Inclusion of oral fluid as a new matrix in the federal program will enhance the DFWP
- Currently developing the MRO Guidance Manual for Oral Fluid
- Oral Fluid Collection Procedures and Collection Manual
- Developing the NLCP Program Documents

Oral Fluid Mandatory Guidelines

- Laboratories could use an alternative method other than immunoassay for the initial test.
- Testing for parent drug (i.e., THC, the psychoactive component of cannabis) is very important for other uses including Driving Under the Influence of Drugs (DUID).
- Establish an Implementation Date for HHS Certification of Laboratories.

Hair Mandatory Guidelines

- An internal draft of the proposed Mandatory Guidelines for Federal Workplace Drug Testing using Hair
- Unique metabolites continue to be studied.
- Effectiveness of decontamination procedures are being studied
- Comments and recommendations have been received from HHS Operational Divisions within HHS
- Scientific and technical issues are being addressed through literature or specific studies
- Other issues will be addressed through public comment and questions in the preamble

Proposed Mandatory Guidelines

Proposed Mandatory Guidelines using Hair

- DTAB recommendation was to pursue hair testing as an alternative matrix
 - 1) *decontamination* of hair specimens and
 - 2) *hair color impact*.
- As recommended by DTAB, development of the proposed Mandatory Guidelines using Hair has attempted to address these specific scientific issues for the use of hair as a drug testing specimen.
- The proposed Mandatory Guidelines using hair is currently under review based on the recommendations and comments.

Patients and Communities Act, P.L. 115-271

Status Report on Hair Testing

- Requires the Secretary of HHS to report to Congress on the status of the final notice for the statutorily-required scientific and technical guidelines for hair testing, within 60 days of enactment of the Act and annually thereafter, until the agency publishes a final notice of guidelines for hair testing.
- There is also a provision to the extent practicable to eliminate the risk of a positive test result caused by the drug use of others and not caused by the drug use of the individual.
- Fighting Opioid Abuse in the Transportation Act 2018.

Advantages of Hair Testing

- Directly observed specimen collection
- Non-invasive specimen collection
- Difficult to adulterate or substitute
- Readily available sample, depending on length of hair tested
- Drug metabolites are present in hair as early as one week after most recent use.

Child Adolesc Psychiatric Clin N Am 25 (2016) 549-565 <https://dx.doi.org/10.1016/j.chc.2016.02.005> 

Mandatory Guideline Routing Process



MRO Guidance Manual Update

- Major Issues that have been addressed
 - Addressing the addition of Rx opioid drugs to drug testing panel: oxycodone, oxymorphone, hydrocodone, hydromorphone.
 - Hydrocodone combination drugs have been rescheduled to Schedule II
 - Consideration of a valid prescription under the Drug-Free Workplace Programs
 - Expired Prescriptions
- Mandatory Guidelines for Federal Workplace Drug Testing Programs
 - Subpart M – Medical Review Officer (MRO), Section 13.1



Patients and Communities Act, P.L. 115-271

Fentanyl

Sec. 4106. Requires the Secretary of HHS to determine, within 180 days

(A) determine whether a revision of the Mandatory Guidelines for Federal Workplace Drug Testing Programs to expand the opiate category on the list of authorized substance testing to include fentanyl is justified, based on the reliability and cost-effectiveness of available testing; and

(B) consider whether to include with the determination under subparagraph (A) a separate determination on whether a revision of the Mandatory Guidelines for Federal Workplace Drug Testing Programs to expand the list of substances authorized for testing to include any other drugs or other substances listed in schedule I and II of section 202 of the Controlled Substances Act ([21 U.S.C. 812](#)) is justified based on the criteria described in subparagraph (A).

Ongoing Studies

- Cannabidiol (CBD) Study
 - Start date: June 2018
- Pharmacokinetics and Pharmacodynamics Study: Oral, Smoked, and Vaporized CBD
 - Disposition of CBD / Cannabinoids in Oral Fluid and Whole Blood after Vaporized and Smoked Cannabis
 - Pharmacodynamic Comparison of CBD / Cannabinoids Following Oral, Smoked, and Vaporized Administration
- Gathering Opioid Data under the Revised Mandatory Guidelines using Urine
 - pH changes
 - Invalid Results
 - Substitution / Adulteration

Epidiolex

- Epidiolex[®] is an FDA approved cannabinoid product. Approved in June 2018 for the treatment of young patients (over two years old) with seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
- Epidiolex sold as an oral solution.
- Epidiolex is the first FDA- approved drug that contains a purified drug substance derived from marijuana -- CBD -- and the first treatment for Dravet syndrome.
- Epidiolex is a Scheduled V drug
- All other CBD products remain Schedule I

Emerging Issues/Synthetic Drugs

- Reemergence of a new synthetic marijuana
- DUID and Marijuana Laws
- CBD Studies being completed
- Other potential problems with synthetic drugs are the lack of a rapid and cost-effective means to identify the substances



Synthetic Marijuana



Marijuana Plant



Shatter

Electronic Federal Chain of Custody Forms

Charles LoDico, M.S., F-ABFT
Senior Chemist

ECCF Approved Laboratory

Lab Category	% of Total ECCF	FormFox	eScreen	LabCorp
2	11.66%			X
2*	0.00%	X		
3	9.06%			X
4	6.64%	X		X
4	34.90%		X	
4**	13.97%	X	X	
5	20.52%	X	X	
5	22.97%	X	X	
5	10.84%			X
6	9.97%	X	X	
6	27.51%		X	
6	16.96%	X	X	

*Approved for ECCF use Apr '18

**Lab withdrew from program Mar '18

Total Federal ECCF Used

Category	Total Regulated Specimens	Percent of All Labs Total Regulated	Total Federal ECCF	Percent of Total ECCF
2*	58,442	0.93%	0	0.00%
2	96,550	1.54%	11,253	11.66%
CAT 2 Total	154,992	2.47%	11,253	10.45%
3	107,436	1.71%	9,737	9.06%
CAT 3 Total	107,436	1.71%	9,737	9.06%
4**	142,151	2.26%	19,852	13.97%
4	217,164	3.46%	14,419	6.64%
4	317,844	5.06%	110,920	34.90%
CAT 4 Total	677,159	10.78%	145,191	21.44%
5	458,659	7.30%	94,106	20.52%
5	480,127	7.64%	110,289	22.97%
5	420,623	6.69%	45,594	10.84%
CAT 5 Total	1,359,409	21.63%	249,989	18.39%
6	1,008,840	16.05%	100,541	9.97%
6	700,756	11.15%	192,782	27.51%
6	1,239,888	19.73%	210,258	16.96%
CAT 6 Total	2,949,484	46.94%	503,581	17.07%
Totals	5,248,480		919,751	17.52%
Total Regulated Specimens (all labs)	6,283,687	83.53%		

*Approved for ECCF use Apr '18

**Lab withdrew from program Mar '18

Total Federal ECCF (Sep '17 – Aug '18)

	HHS-Certified Laboratory												
Period	A	B	C	D	E	F	G	H	I	J	K	L	Grand Total
2015												3,172	3,172
2016			-	-		-	-	-	1,087	-	26,403	82,656	110,146
2017		4,482	5,574	8,444	21,827	22,531	31,669	35,334	41,578	59,207	92,122	150,537	473,305
Jan		554	795	946	3,719	3,056	4,843	4,663	6,627	8,825	4,972	13,999	52,999
Feb		583	810	1,055	4,443	3,515	6,072	6,113	7,667	10,702	6,056	14,849	61,865
Mar		718	1,122	1,406		4,246	11,511	12,458	9,728	21,895	11,329	18,421	92,834
Apr	0	705	937	1,250		4,148	11,216	13,028	10,225	21,728	10,452	16,772	90,461
May	0	1,012	1,145	1,432		4,402	12,407	15,291	10,966	24,537	11,323	18,016	100,531
Jun	-	1,021	1,171	1,509		4,671	11,916	15,138	11,404	27,345	10,985	18,033	103,193
Jul	-	1,110	1,160	1,126		4,402	11,194	13,546	12,004	31,805	10,083	17,478	103,908
Aug	-	1,675	1,449	1,866		5,975	11,510	16,041	13,884	39,588	12,348	21,183	125,519
Jan-Aug 2018	-	7,378	8,589	10,590	8,162	34,415	80,669	96,278	82,505	186,425	77,548	138,751	731,310

Use of Unapproved ECCF's

- Definitions and requirements for the use of a Federal ECCF are in the NLCP Manual (for Urine Laboratories; for Urine IITFs)
- Laboratories must receive approval from SAMHSA prior to accepting regulated specimens collected using an ECCF system.
- If a laboratory receives a specimen that was collected using an ECCF system whose use has not been approved by SAMHSA for that laboratory, the laboratory must reject the specimen.

Unapproved ECCF's

A. Employer Name, Address, I.D. No. BAX INDUSTRY INC 12345 SOUTH CENTRAL LANE AVE RESEARCH TRIANGLE PARK NC 27709 PHONE (919) 415-5789 FAX (919) 631-0154		B. MRO Name, Address, Phone No. and Fax No. DOE, JOHN MD 123 ANYWHERE AVE RALIEGH NC 27519 PHONE (877) 898-4343 FAX (919) 545-8978	
C. Donor SSN or Employee I.D. No. _____		D. Specify Testing Authority: <input type="checkbox"/> HHS <input type="checkbox"/> NRC <input type="checkbox"/> FAA <input type="checkbox"/> FRA <input type="checkbox"/> FTA <input type="checkbox"/> PHMSA <input type="checkbox"/> USCG Specify DOT Agency: <input checked="" type="checkbox"/> MCSA	
E. Reason for Test: <input checked="" type="checkbox"/> Pre-employment <input type="checkbox"/> Random <input type="checkbox"/> Reasonable Suspicion/Cause <input type="checkbox"/> Post Accident <input type="checkbox"/> Return to Duty <input type="checkbox"/> Follow-up <input type="checkbox"/> Other (specify) _____		F. Drug Tests to be Performed: <input checked="" type="checkbox"/> THC, COC, PCP, OPI, AMP <input type="checkbox"/> THC & COC Only <input type="checkbox"/> Other (specify) _____	
65304N DOT DRUG PANEL w/TS			
G. Collection Site Name: CARE-STOP RESEARCH LANE Address: 12345 S. MAIN ST. City, State and Zip: RESEARCH AVE 27856		Collection Site Code: _____ Collector Phone No.: (919) 545-8978 Collector Fax No.: (877) 898-4343	
STEP 2: COMPLETED BY COLLECTOR (make remarks when appropriate) Collector reads specimen temperature within 4 minutes. Temperature between 90° and 100° F? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No, Enter Remark: _____ Collection: <input checked="" type="checkbox"/> Split <input type="checkbox"/> Single <input type="checkbox"/> None Provided, Enter Remark: _____ <input type="checkbox"/> Observed, (Enter Remark) _____			
STEP 3: Collector affixes bottle seal(s) to bottle(s). Collector dates seal(s). Donor initials seal(s). Donor completes STEP 5 on Copy 2 (MRO Copy) STEP 4: CHAIN OF CUSTODY - INITIATED BY COLLECTOR AND COMPLETED BY TEST FACILITY			
I certify that the specimen given to me by the donor identified in the certification section on Copy 2 of this form was collected, labeled, sealed, and released to the Delivery Service noted in accordance with applicable Federal requirements.		SPECIMEN BOTTLE(S) RELEASED TO: Courier	
Signature of Collector: [Signature] BURN		Date (Mo./Day/Yr.): 04 03 2018 Time of Collection: 03:30 AM	
(Print) Collector's Name (First, MI, Last)		Name of Delivery Service	
RECEIVED AT LAB OR IITF: <input checked="" type="checkbox"/>		Primary Specimen Bottle Seal Intact <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No If No, Enter remarks in Step 5A.	
Signature of Accessioner: [Signature] (Print) Accessioner's Name (First, MI, Last)		SPECIMEN BOTTLE(S) RELEASED TO: APR 04 2018 Date (Mo./Day/Yr.)	

Standard Variables

ATTENTION: HHS-Certified and Applicant Laboratories and Instrumented Initial Test Facilities (IITFs), and NLCP Inspectors

Subject: Electronic Report Terminology Follow-Up

The attached National Laboratory Certification Program (NLCP) Notice serves as a follow-up to the Electronic Report Terminology Notice sent on February 6, 2018, concerning the terminology to be used on computer-generated electronic reports for federally regulated specimens.

If you have any questions concerning this notice, please contact NLCP staff (919) 541-7242 or nlcp@rti.org.

Standard Variables for Electronic Reporting

Drug Testing Advisory Board Working Group on Standard Variables and Electronic Reporting

This Working Group will be lead by Dr. Barry Sample, Quest Diagnostics Inc.

- What is a Standard Variable?
- How do Standard Variables cross over between matrices: Urine, Oral Fluid, Hair
- Standard Variables captured on the Federal Chain of Custody Form
- Benefit to HHS Certified Laboratories in reporting methods
- Benefit to the regulated industry in reporting standard information

Standard Variables

Type	Fields	Description
Specimen		
	RecordID	Unique Record ID used to match with Drug Records
	CCFID	Custody and Control Form ID number
	RegulatoryAuthority	Regulatory Authority: DOT, NDOT, HHS, NRC
	RegulatoryAgency	Regulatory Agency: FAA, FRA, FMCSA, etc
	EmployeeCategory	DOT Employee Category (Not Currently Used)*
	Reason	Reason For Test
	STATUS	Specimen Status*
	OrderedDate	Date the Drugtest was ordered by employer
	ScheduledDate	Date the Drugtest was scheduled with the Lab/Clinic Network
	ExpirationDate	Date the Drugtest scheduled event was to expire*
	ElectronicOrderID	The electronic Order ID that follows the Chain of Custody throughout its lifecycle (Registration ID, Barcode Authorization Code, Passport ID, etc.)*
	Reconfirm	(Y/N) Disposition reconfirmation test

*Field not captured in database

Standard Variables

Type	Fields	Description
Employer Info		
	EmployerID	Donor Employer ID
	EmployerName	Employer Full Name
	EmployerHierID1	Employer Heirarchy 1 ID, such as subsidiary
	EmployerHierName1	Employer Hierarch 1 Name
	EmployerHierID2	Employer Heirarchy 2 ID, such as division
	EmployerHierName2	Employer Hierarch 2 Name
	EmployerHierID3	Employer Heirarchy 3 ID, such as group
	EmployerHierName3	Employer Hierarch 3 Name
	EmployerLocationID	Employer Location ID
	EmployerLocationName	Employer Location Name
	EmployerLocationAddress	Employer Location Address
	EmployerLocationAddress2	EmployerLocation Address 2
	EmployerLocationAddress3	Employer Location Address 3
	EmployerLocationCiry	Employer Location City
	EmployerLocationState	Employer Location State
	EmployerLocationZip	Employer Location Zip
	EmployerLocationCountry	Employer Location Country
	EmployerLabAccount	Employer Lab Account
	OtherEmployerID	Other Employer ID (Node ID)*

*Field not captured in database

Standard Variables

Type	Fields	Description
Clinic		
	collectionsiteID	Clinic ID
	Collectionsitename	Clinic Name
	CollectionSiteAddress	Clinic Address
	CollectionSiteAddress2	Clinic Address 2
	CollectionSiteAddress3	Clinic Address 3
	CollectionSiteCity	Clinic City
	CollectionSiteState	Clinic State
	CollectionSiteZip	Clinic Zip
	Collectionphone	Clinic Phone Number
	OnsiteCollection	(Y/N) Onsite Collection?
	SplitCollection	(Y/N) Split collection?
	ObservedCollection	(Y/N) Collection Observed?
	TemperatureInRange	(Y/N) Temperature in Range?
	DrugtestRefusal	Drug Test Refusal Indicator (Adulterated, Substituted, Shy Bladder, Other)
	ClinicCollectionDate	Date specimen collected
	ClinicComments	Remarks about collection

*Field not captured in database

Standard Variables

Type	Fields	Description
Laboratory		
	LabID	(ID) Laboratory performing test
	LabName	Lab Name
	LabLocationID	Laboratory Location ID*
	LabLocationName	Laboratory Location Name*
	LabAddress1	Laboratory Address*
	LabAddress2	Laboratory Address 2*
	LabAddress3	Laboratory Address 3*
	LabCity	Laboratory City*
	LabState	Laboratory State*
	LabZip	Laboratory Zip
	LabSpecimenReceivedDate	Date specimen received at lab
	LabResultReportedDate	Date lab reported disposition of specimen
	LabAccessionNumber	Laboratory Accession number used by labs to reference specimen
	LaboratorySpecimenDisposition	Laboratory Disposition (Result)
	Dilute	Dilute Indicator (Y/N)
	CreatinineLevel	Creatinine Level*
	SpecificGravity	Specific Gravity Level*
	pHLevel	pH Level*
	LabComments	Laboratory Comments

*Field not captured in database

Standard Variables

Type	Fields	Description
MRO/TPA		
	TPAorMRO	TPA or MRO indicator (T, M, B)*
	SpecNo	MRO Specimen Number
	DateLoaded	Date Specimen Info loaded in system by MRO
	DateCOCCRec	Date CCF received by MRO
	MROComments	MRO Comments
	MROVerificationDate	Date MRO Verified specimen disposition
	MROSpecimenDisposition	MRO Overall Disposition
	Explaincode	MRO Disposition Explanation Code
Specimen Information		
	prodcode	Product Code (Drug Test, Alcohol Test)
	ProdCat	Product Category (Drug Test, Alcohol Test)
	ProdClass	Product Classification (Blood, Breath Alcohol Test, Hair, Oral, Saliva, Urine)
	SpecType	Specimen Type (HHS DOT Mirror, 5Panel, 9Panel+Nit, etc.)
	PanelID	Lab Panel ID
	PanelDescription	Lab Panel Description
	Blind	Blind Panel (Y/N)

*Field not captured in database

Standard Variables

Type	Fields	Description
Drug Records		
	RecordID	Unique Record ID used to match with Drug Records
	SequenceNumber	Sequence Number starting with 1 within the Record ID
	DrugID	Drug ID
	name	Drug Name
	DrugClassification	Drug Classification (Drug Class that the drug test is associated with)*
	Screening	Screening Level*
	Confirmation	Confirmation Level*
	Quantification	Quantification Level
	LabDisposition	Lab Disposition for this Drug
	MRODisposition	MRO Disposition for this Drug
	MROComments	MRO Comments**

*Field not captured in database

**Field removed from DOI data 10/2014

Standardization of Analytes

Drug Class	Urine	Oral Fluid	Hair	Abbreviations
Amphetamines	Amphetamine	Amphetamine	Amphetamine	AMP
	Methamphetamine	Methamphetamine	Methamphetamine	MAMP
	Methylenedioxymethamphetamine	Methylenedioxymethamphetamine	Methylenedioxymethamphetamine	MDMA
	Methylenedioxyamphetamine	Methylenedioxyamphetamine	Methylenedioxyamphetamine	MDA
Cocaine		Cocaine	Cocaine	COC
	Benzoyllecgonine	Benzoyllecgonine	Benzoyllecgonine	BZE
Marijuana	Δ -9-tetrahydrocannabinol-9-carboxylic acid		Δ -9-tetrahydrocannabinol-9-carboxylic acid	THCA
		Tetrahydrocannabinol		THC
Phencyclidine	PCP	PCP	PCP	PCP
Opioids	Codeine	Codeine	Codeine	COD
	Morphine	Morphine	Morphine	MOR
	Hydrocodone	Hydrocodone	Hydrocodone	HYC
	Hydromorphone	Hydromorphone	Hydromorphone	HYM
	Oxycodone	Oxycodone	Oxycodone	OXYC
	Oxymorphone	Oxymorphone	Oxymorphone	OXYM
	6-Acetylmorphine	6-Acetylmorphine	6-Acetylmorphine	6-AM

Standardization of Analytes

Drug Class	Oral Fluid	Hair	Unique Metabolites	Abbreviations
Amphetamines	Amphetamine	Amphetamine	Amphetamine	AMP
	Methamphetamine	Methamphetamine	Methamphetamine	MAMP
	Methylenedioxymethamphetamine	Methylenedioxymethamphetamine	Methylenedioxymethamphetamine	MDMA
	Methylenedioxyamphetamine	Methylenedioxyamphetamine	Methylenedioxyamphetamine	MDA
Cocaine	Cocaine	Cocaine		COC
	Benzoyllecgonine	Benzoyllecgonine		BZE
			Hydroxy Cocaine	HCOC
			Ecognine Methyl Ester	EME
Marijuana		Δ -9-tetrahydrocannabinol-9-carboxylic acid	Δ -9-tetrahydrocannabinol-9-carboxylic acid	THCA
	Tetrahydrocannabinol			THC
Phencyclidine	PCP	PCP	PCP	PCP
Opioids	Codeine	Codeine	Codeine	COD
	Morphine	Morphine	Morphine	MOR
	Hydrocodone	Hydrocodone	Hydrocodone	HYC
	Hydromorphone	Hydromorphone	Hydromorphone	HYM
	Oxycodone	Oxycodone	Oxycodone	OXYC
	Oxymorphone	Oxymorphone	Oxymorphone	OXYM
	6-Acetylmorphine	6-Acetylmorphine	6-Acetylmorphine	6-AM

Thank You
Division of Workplace Programs

Please Visit our Website

<https://www.samhsa.gov/workplace>